AstraZeneca PLC (AZN) Stock Valuation: P/E Ratio and Intrinsic Value
Is AstraZeneca PLC stock expensive or cheap? This page shows the price-earnings ratio of AstraZeneca PLC for the last fiscal years, the current share price, and beta and volatility as risk measures. Earnings figures come from the company's published filings (FY 2025).
Earnings basis for the valuation (FY 2025)
| Revenue | 58.74 USD bn |
|---|---|
| Net income | 10.22 USD bn |
| Net margin | 17.4 % |
How the AstraZeneca PLC P/E ratio is calculated
The price-earnings ratio divides the share price by earnings per share. On this page the ratio is shown per fiscal year, so you can see whether today's valuation of AstraZeneca PLC is above or below its own history. Beta and volatility indicate how strongly the share moves compared with the overall market.
Frequently asked questions about AstraZeneca PLC
What is the AZN P/E ratio?
The P/E ratio divides the AstraZeneca PLC share price by earnings per share. This page shows the ratio for each of the last fiscal years, so the current valuation of AZN can be compared with its own history.
Is AstraZeneca PLC stock overvalued or undervalued?
There is no single answer. A useful check is whether the current P/E of AZN is above or below its multi-year average and how earnings, margins and revenue are developing. This page shows all of these figures from the published filings.
How can I estimate the intrinsic value of AstraZeneca PLC?
An intrinsic value estimate needs earnings or free cash flow, a growth assumption and a discount rate. This page provides the reported earnings basis, margins and the valuation history of AZN as the starting point.